Live cell imaging is the procedure to concentrate live cells with the assistance of pictures got from imaging frameworks like high substance screening frameworks and magnifying lens. This strategy is utilized by the researchers to acquire a superior perspective on the cell's natural capacity by considering the phone elements. As of late, live cell imaging innovation has been broadly acknowledged by different specialists to get a superior information with respect to cell science. Live cell imaging assumes a urgent part in research fields like nervous system science, immunology, microbiology and, hereditary qualities among others.
The live cell imaging market is expected to grow at a CAGR of 8.7% from 2021 to 2027, to reach USD 3,769.7 million by 2027 from USD 2,156.5 million in 2020.
Climb in the amount of infection cases close by extension in the amount of government resources for R&D practices are needed to be the driving segment in the market later on years. Usage of live cell imaging in the field of tweaked medicine is depended upon to give improvement openings in the live cell imaging market during the guess time span.
The market for live cell imaging is driven basically by the variables like the developing appropriation of high-content screening strategies in drug disclosure, rising rate of malignancy, development in research subsidizing, and rising government financing in regenerative medication research. In any case, significant expense of high-content screening frameworks will upset the general appropriation of live cell imaging frameworks and in this way limit market development in the coming years.
According to the World Health Organization (WHO), chronic disease is predictable to increase by 57% by the year 2020. Increasing prevalence of chronic disease demanding higher & quicker diagnostic facilities boost the growth of live cell imaging market
The live cell imaging market is segment into by product type, by technology, by application, by end-user and by region, Based on product type, the market is segmented into instruments, kits and reagents, software, consumables. Instruments is further sub-segmented into standalone systems, cell analyzers, microscopes and image capturing devices. Based on technology, the market is segmented into fluorescence recovery after photobleaching, fluorescence resonance energy transfer, high-content analysis, fluorescence in situ hybridization, others. Based on by application, the market is segmented into drug discovery, cell biology, developmental biology, stem cells, others. Based on end-user, the market is segmented into hospitals, healthcare companies, diagnostic laboratories, others.
Global Live Cell Imaging Market Forecast 2019-2027 (US$ Mn)
Source: Precise Market Intelligence, 2020
The market has been segmented based on product type, technology, application, and region.
• By Product Type
Microscopes and Image Capturing Devices
o Kits and Reagents
• By Technology
o Fluorescence Recovery After Photobleaching
o Fluorescence Resonance Energy Transfer
o High-content Analysis
o Fluorescence In Situ Hybridization
• By Application
o Drug Discovery
o Cell Biology
o Developmental Biology
o Stem Cells
• By End-use
o Healthcare Companies
o Diagnostic Laboratories
• By Region
o North America (U.S., Canada)
o Europe (U.K., France, Germany, Italy, Spain, and rest of Europe)
o Asia Pacific (China, Japan, India, and Rest of Asia Pacific)
o South America (Brazil, Mexico, and Rest of South America)
o Middle East & Africa (Saudi Arabia, UAE, South Africa, and Rest of Middle East & Africa)
Global Live Cell Imaging Market, By Region, 2020
Source: Precise Market Intelligence, 2021
In terms of region, North America is expected to account for larger market share, followed by Europe. During the forecast period, the APAC market is assessed to enlist the most elevated CAGR during the figure time frame. The development in this market can be credited to the public authority activities for research on undeveloped cell treatment, expanding maturing populace, the rising noticeable quality of regenerative medication research, expanding number of specialists in Japan, development of preclinical/clinical examination in China, ideal changes in unfamiliar direct speculation (FDI) guidelines in the drug business in India, and development of the drug and biopharmaceutical areas in South Korea.
The prominent companies in the market are; Danaher Corporation, Carl Zeiss AG, Olympus Corporation, PerkinElmer, Inc., GE Healthcare, Thermo Fisher Scientific Inc., Sartorius AG, BioTek Instruments, Sigma-Aldrich, Bio-Rad Laboratories, Becton, Dickinson and Company, Nikon Corporation, Molecular Devices, Bruker and Others